Articles Accepted

Etoposide is a well-known anti-tumour agentused to treat a wide range of cancers.Although it is a BCS class IV drug, applications are restricted due to poor solubility and bioavailability. Hence, the current researchwas designed to overcome these pitfalls. Sixteenformulation batches were developedusingthe physical mixture and kneading method and optimized. A selected batch was evaluated using Solubility, Differential scanning calorimetry, X-ray diffraction, scanning electron microscopy, Fourier transform infrared (FTIR),Gastrointestinaldistribution,Pharmacokinetic, andCytotoxicity study.The results manifested the saturated solubility of the formulation was19.76 mgmL-1. FTIR showedC-O=1646 cm-1, and C-H=2956 cm-1. The distribution study indicated4.99, 9.35, and 3.21 µgmL-1 colon concentrations at 8, 16, and 24h, respectively. The Cmax and AUC were foundat 741.17±12.29ngmL-1 and 3089.23 ±34.69 ngmL-1 with less viability on Hela cells. Therefore, the study explored the developed solid dispersions enhanced solubility and bioavailability with an antiproliferative effect.